Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immunome (IMNM) Short-term Investments (2023 - 2025)

Immunome's Short-term Investments history spans 3 years, with the latest figure at $124.2 million for Q2 2025.

  • For Q2 2025, Short-term Investments rose 9.86% year-over-year to $124.2 million; the TTM value through Jun 2025 reached $124.2 million, up 9.86%, while the annual FY2024 figure was $74.0 million, 87.4% up from the prior year.
  • Short-term Investments reached $124.2 million in Q2 2025 per IMNM's latest filing, up from $59.7 million in the prior quarter.
  • In the past five years, Short-term Investments ranged from a high of $124.2 million in Q2 2025 to a low of $39.5 million in Q4 2023.
  • Average Short-term Investments over 3 years is $76.4 million, with a median of $74.0 million recorded in 2024.
  • Peak YoY movement for Short-term Investments: skyrocketed 87.4% in 2024, then increased 9.86% in 2025.
  • A 3-year view of Short-term Investments shows it stood at $39.5 million in 2023, then skyrocketed by 87.4% to $74.0 million in 2024, then soared by 67.89% to $124.2 million in 2025.
  • Per Business Quant, the three most recent readings for IMNM's Short-term Investments are $124.2 million (Q2 2025), $59.7 million (Q1 2025), and $74.0 million (Q4 2024).